<DOC>
	<DOCNO>NCT02261376</DOCNO>
	<brief_summary>This open label , non-randomised , single-dose , parallel-group study 48 healthy subject enrol 4 cohort - Caucasian men , age 18-55 year , Caucasian men , age 65 year old , Japanese men , age 18-55 year , Caucasian woman , age 18-55 year .</brief_summary>
	<brief_title>Effects Age , Gender &amp; Race Pharmacokinetics ( PK ) DS-1971a</brief_title>
	<detailed_description />
	<criteria>Healthy volunteer : Cohort 1 : Caucasian men , age 1855 year Cohort 2 : Caucasian men , 65 year old Cohort 3 : Japanese men , age 1855 year Cohort 4 : Caucasian woman , age 1855 year For purpose determine eligibility , age calculate day dose administration Caucasian subject ( Cohorts 12 4 ) must 4 Caucasian grandparent . Japanese subject ( Cohort 3 ) must 4 ethnically Japanese grandparent , Japanese passport , live outside Japan longer 5 year . Female subject ( Cohort 4 ) must nonchildbearing potential , follow : must postmenopausal ( last menstrual period least 12 month ago , folliclestimulating hormone ( FSH ) test screen confirms post menopausal status ) ; must surgically sterile , undergone hysterectomy , bilateral oophorectomy , bilateral salpingectomy and/or bilateral tubal ligation . A BMI range 1830 kg/m2 , inclusive , weigh 50 100 kg screening . Willing comply study restriction , include use contraception , concomitant medication , dietary lifestyle restriction . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . Have give write consent participate read information consent form , opportunity discuss trial investigator his/her delegate . 9 . Have give write consent his/her data enter The Overvolunteering Prevention System ( TOPS ) . Clinically relevant abnormal history , physical finding , ECG finding , laboratory value could interfere objective study safety subject . Presence history acute chronic illness , include ( limited ) liver kidney disease , hypertension , seizure , know impairment endocrine , specific bodyorgan dysfunction . Presence history severe adverse reaction medicine . Presence history malignant disease . Acute chronic infectious disease , include human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) C virus ( HCV ) infection . Surgery ( eg stomach bypass ) medical condition might affect absorption medicine . Significant illness within 4 week dose study medication . Participation another clinical trial new chemical entity prescription medicine within previous 3 month , unwilling abstain participate clinical trial study 3 month receipt study medication . Participation another clinical study DS1971a . Blood pressure ( BP ) heart rate semisupine position screen examination outside range 90140 mm Hg systolic , 4090 mm Hg diastolic ; heart rate 40100 beats/min . Subjects Stage 1 hypertension ( systolic 140160 mmHg ; diastolic 90100 mmHg ) may enrol provide evidence endorgan damage , diabetes 10 year cardiovascular risk &gt; 20 % . Abnormal ECG waveform morphology screen would preclude accurate measurement QT interval duration . Corrected QT interval ( Fridericia 's formula ) ( QTcF ) interval duration &gt; 430 msec men &gt; 450 msec woman , obtain average measurement duplicate screen ECGs . Estimated glomerular filtration rate ( eGFR ) &lt; 80 mL/min/1.73 m2 ( young subject , Cohorts 1 , 3 4 ) &lt; 70 mL/min/1.73 m2 ( old subject , Cohort 2 ) absolute creatinine value upper limit normal range . eGFR estimate use modification diet renal disease [ MDRD ] equation ) . Use prescription medicine counter ( OTC ) medication , herbal remedy ( St John 's wort ) , know strong inhibitor strong inducer cytochrome ( CYP ) enzyme ( also know CYP450 enzyme ) 30 day dose trial medication ; use prescription OTC medicine ( except permit ) , include dietary supplement herbal remedy , 7 day first dose trial medication . Consumption certain food beverage dose throughout study period . Loss 400 mL blood 3 month trial , e.g. , blood donor . Abuse drug alcohol 2 year first dose study medication , intake 21 unit alcohol weekly ( men ) 14 unit alcohol weekly ( woman ) . Smoking 10 cigarette Â½ ounce tobacco daily unwilling stop smoking study . Likely possibility volunteer cooperate requirement protocol . Objection General Practitioner ( GP ) volunteer enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>